Denosumab cost effectiveness study

Denosumab for Elderly Men with Osteoporosis: A Cost ...

★ ★ ★ ☆ ☆

12/9/2015 · With the exception of the cost-effectiveness study in elderly Swedish men , which used the Markov model structure used in the current analysis, we do not know any other published studies that evaluated the cost-effectiveness of different osteoporotic treatments in older men with osteoporosis. In the study of costs in Sweden, denosumab was ...

Denosumab for Elderly Men with Osteoporosis: A Cost ...

Cost-utility of denosumab for the treatment of ...

★ ★ ★ ★ ☆

2/9/2015 · The objective of this study was to estimate the cost- effectiveness of denosumab for osteoporotic fracture prevention compared with generic bisphosphonates (alendronate, ibandronate, risedronate), strontium ranelate, and no treatment in a cohort of postmenopausal Spanish women.

Cost-utility of denosumab for the treatment of ...

Cost-Effectiveness of Denosumab Compared With Zoledronic ...

★ ★ ★ ★ ★

Given the considerably higher costs of denosumab compared with zoledronic acid, it is important to consider the economic implications of these treatment options from a third-party payer perspective. 21 The objective of this study was to assess the cost-effectiveness of denosumab vs. zoledronic acid in the prevention of SREs in patients with ...

Cost-Effectiveness of Denosumab Compared With Zoledronic ...

Denosumab: A cost-effective alternative for older men with ...

★ ★ ★ ★ ★

In this study, the cost-effectiveness of denosumab compared to other osteoporotic treatments was evaluated in men ≥ 75 years of age (mean 78 years), mean T-score of − 2.12, and 23% prevalent vertebral fractures. Denosumab dominated all the treatment strategies included in the study.

Denosumab: A cost-effective alternative for older men with ...

Denosumab for Prevention of Fractures in Postmenopausal ...

★ ★ ★ ★ ★

Study Design. Our study, called Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM), was an international, randomized, placebo-controlled trial.

Denosumab for Prevention of Fractures in Postmenopausal ...

Denosumab: A Unique Perspective on Adherence and Cost ...

★ ★ ★ ☆ ☆

Study Selection and Data Extraction: All English-language clinical trials on adherence (as compliance and persistence) or patient preference for denosumab compared with oral bisphosphonates were evaluated. In addition, articles analyzing the cost-effectiveness of …

Denosumab: A Unique Perspective on Adherence and Cost ...

Cost-effectiveness of Denosumab for the treatment of ...

★ ★ ★ ★ ★

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis ... cost-effectiveness of denosumab given for up to 5 years to a ... from prescription data and a persistence study ...

Cost-effectiveness of Denosumab for the treatment of ...

What are we paying for? A cost-effectiveness analysis of ...

★ ★ ★ ☆ ☆

10/13/2016 · The base-case incremental cost per QALY gained for denosumab versus alendronate was $246,749. There is a near zero probability that denosumab is cost-effective at a threshold value of $100,000 per QALY gained. If the price of denosumab was reduced by 50 %, the incremental cost per QALY gained falls to $50,068.

What are we paying for? A cost-effectiveness analysis of ...

Efficacy and Safety of Denosumab for the Treatment of Bone ...

★ ★ ☆ ☆ ☆

6/13/2012 · Although the direct cost of denosumab is higher than zoledronic acid for patients with bone metastases (Table 2), in assessments including prolongation of the time to SREs, a cost-effectiveness study performed in the USA reported that denosumab is more cost-effective than zoledronic acid . Therefore, the standard medical treatment for bone ...

Efficacy and Safety of Denosumab for the Treatment of Bone ...

Cost-effectiveness of denosumab in the treatment of ...

★ ★ ★ ☆ ☆

Request PDF on ResearchGate | Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada | Abstract Objective Denosumab is a novel biologic agent approved in Canada ...

Cost-effectiveness of denosumab in the treatment of ...

Osteoporosis Drug Denosumab Shows Benefit to 8 Years

★ ★ ☆ ☆ ☆

The FREEDOM Extension study shows a prolonged effect of treatment with the osteoporosis drug denosumab out to 8 years of therapy, albeit with caveats that could explain some of these findings.

Osteoporosis Drug Denosumab Shows Benefit to 8 Years

Cost–effectiveness of denosumab as a bone protective agent ...

★ ★ ★ ★ ★

with castration resistant prostate cancer Expert Rev. Pharmacoecon. Outcomes Res. 16(1), 5–10 (2016) ... novel agents are nowadays available for the management of patients with castration-resistant prostate cancer (CRPC). Denosumab is a new bone-protective agent, ... study the cost–effectiveness of denosumab in patients with CRPC.

Cost–effectiveness of denosumab as a bone protective agent ...

Cost-effectiveness Analysis of Denosumab in the Prevention ...

★ ★ ★ ★ ★

Cost-effectiveness Analysis of Denosumab in the Prevention of Skeletal-related Events in Patients with Prostate Cancer in Kazakhstan. Introduction. Bone mass loss (BML) is one of the adverse effects of oncological chemotherapy, especially in cases of hormonal types of cancer, such as a prostate cancer (PC). ... the purpose of the present study ...

Cost-effectiveness Analysis of Denosumab in the Prevention ...

Denosumab - National Cancer Institute

★ ★ ★ ★ ☆

Aims: This study assessed the cost-effectiveness of the subcutaneous RANKL inhibitor, denosumab, vs the intravenous bisphosphonate, zoledronic acid, for the prevention of skeletal-related events (SREs) in patients with prostate cancer, breast cancer, and other solid tumors (OST) in the Czech Republic.

Denosumab - National Cancer Institute

Cost-effectiveness of denosumab versus zoledronic acid for ...

★ ★ ☆ ☆ ☆

3/15/2018 · Probability of denosumab being cost-effective vs ZA (societal vs payer perspective) = 63% vs 60%; Taking into account a wide range of costs and benefits, denosumab was found to be a cost-effective option for the prevention of SREs in MM in comparison to ZA, from both a societal and payer perspective. A positive NMB was also attributed to denosumab.

Cost-effectiveness of denosumab versus zoledronic acid for ...

Denosumab is cost-effective for the prevention of SREs in ...

★ ★ ★ ★ ★

10/30/2017 · Shapiro and colleagues used a Markov model to compare the cost-effectiveness of 4 mg IV zoledronic acid monthly, 4 mg IV zoledronic acid every 3 months and …

Denosumab is cost-effective for the prevention of SREs in ...

Zoledronic acid more cost-effective than denosumab for ...

★ ★ ★ ☆ ☆

Therefore, we conducted a cost-effectiveness analysis comparing denosumab with zoledronic acid (ZA) for SRE prevention in patients with MM from the national healthcare system perspective in a representative sample of European countries: Austria, Belgium, Greece, and Italy.

Zoledronic acid more cost-effective than denosumab for ...

A cost-effectiveness analysis of denosumab for the ...

★ ★ ★ ☆ ☆

Moreover, the majority of patients will patients do not adhere. discontinue treatment with alendronate and, as discussed The present study also showed that cost-effectiveness of below, the higher the risk of non-adherence, the better the denosumab improved markedly …

A cost-effectiveness analysis of denosumab for the ...

Cost-effectiveness of Denosumab for the treatment of ...

★ ★ ★ ★ ☆

8/16/2004 · A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.

Cost-effectiveness of Denosumab for the treatment of ...

A Study to Evaluate Denosumab in the Treatment of ...

★ ★ ★ ☆ ☆

4/29/2011 · Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma ... The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma. ... A cost-effectiveness analysis of denosumab for the prevention of skeletal-related ...

A Study to Evaluate Denosumab in the Treatment of ...

Denosumab - Wikipedia

★ ★ ★ ★ ☆

3/20/2015 · Prolia: Another wonder drug that wasn't ... No one seemed to notice that the FDA clinical reviewer Adrienne Rothstein, MD had stated that Prolia denosumab "has the potential to affect multiple layers of the immune system" before its approval and that "three subjects required hospitalization for pneumonia after a single dose.” This is a great ...

Denosumab - Wikipedia

Denosumab Compared to Zoledronic Acid in the Treatment of ...

★ ★ ★ ★ ☆

Subcutaneous denosumab is superior to intravenous zoledronic acid (ZA) for the prevention of skeletal-related events (SREs) in patients with advanced solid tumors and bone metastases. This study sought to determine the lifetime cost-effectiveness of denosumab vs …

Denosumab Compared to Zoledronic Acid in the Treatment of ...